chartexchange

VERA
Vera Therapeutics, Inc. Class A Common Stock
stockNASDAQ

Market OpenNov 19, 2026 3:00:10 PM EST
26.50USD+3.597%(+0.92)601,510
25.43Bid26.64Ask1.21Spread
Loading…
Loading…
Healthcare
Biotechnology
HQ
Brisbane, CA, USA
Previous Close
$25.58
Beta
1.25
52-Week High
$56.05 2025-12-24
52-Week Low
$25.34 2026-11-18
SMA 50
$30.58
SMA 200
$35.87
Avg. Vol 10D
1.36M
Avg. Vol 30D
1.52M
Avg. Vol 90D
1.97M
Relative Vol
0.40
52.62M
12,141,556
0.4300%
1,800,000
VERA Profile

trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.

VERA Performance
PeriodPriceDateChangeBeta
1W29.042026-11-12-8.57%0.755
1M28.922026-10-19-8.20%1.752
3M32.282026-08-19-17.74%1.777
6M33.252026-05-19-20.15%1.085
1Y28.552025-11-19-7.01%1.255
2Y45.902024-11-19-42.16%—
5Y31.202021-11-19-14.90%1.076
VERA Stock Summary

Vera Therapeutics, Inc. Class A Common Stock (NASDAQ:VERA) stock price today is $26.55, and today's volume is 599,841. VERA is up 3.791% today. The 30 day average volume is 1.52M. VERA market cap is $1.92B with 72.30M shares outstanding.